Sugi Predict

Sugi Predict / Compounds / SCHEMBL3133484

SCHEMBL3133484

SCHEMBL3133484

O=S(=O)(Cl)c1nc2cc(Cl)ccc2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ LOXL2 Q9Y4K0 1/20 0.50
▸ IDO1 P14902 1/20 0.50
▸ CA2 P00918 2/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ PPARA Q07869 8/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ PSMB8 P28062 1/20 0.42
▸ PSMB5 P28074 1/20 0.42
▸ KAT8 Q9H7Z6 1/20 0.41
▸ MGAM O43451 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SI P14410 1/20 0.41
▸ MGAM2 Q2M2H8 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14603109 0.86 NPC1 (0.50) SMN1; SMN2CA2PPARANPC1RAB9A
SCHEMBL1748164 0.85 SMN1; SMN2 (0.53) SMN1; SMN2NPSR1LOXL2IDO1CA2
SCHEMBL11653706 0.78 NPC1 (0.51) SMN1; SMN2CA2PPARANPC1RAB9A
SCHEMBL31038171 0.77 PPARA (0.47) SMN1; SMN2NPSR1LOXL2IDO1CA2
SCHEMBL29475393 0.77 PSMB8 (0.70) SMN1; SMN2IDO1CA2NPC1RAB9A
SCHEMBL75415 0.77 PSMB8 (0.70) SMN1; SMN2IDO1CA2NPC1RAB9A
SCHEMBL780242 0.75 SMN1; SMN2 (0.61) SMN1; SMN2NPSR1LOXL2IDO1HDAC6
SCHEMBL11175940 0.74 SMN1; SMN2 (0.51) SMN1; SMN2NPSR1LOXL2IDO1HDAC6
SCHEMBL9849048 0.73 LOXL2 (0.42) SMN1; SMN2NPSR1LOXL2IDO1CA2
SCHEMBL11189027 0.73 F10 (0.48) SMN1; SMN2IDO1NPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2174936-B1 PNA monomer and precursor PANAGENE INC (KR) 2013-09-04 — — EP disclosed
EP-2174936-A1 PNA monomer and precursor Panagene, Inc. (KR) 2010-04-14 — — EP disclosed
EP-1501812-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-12-30 — — EP disclosed
US-7411065-B2 Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids PANAGENE, INC. (KR) 2008-08-12 — — US disclosed
US-7371860-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2008-05-13 — — US disclosed
US-7371859-B2 Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields PANAGENE, INC. (KR) 2008-05-13 — — US disclosed
CN-100347161-C PNA monomer and precursor PANAGENE INC (KR) 2007-11-07 — — CN disclosed
US-7179896-B2 Method of making PNA oligomers PANAGENE, INC. (KR) 2007-02-20 — — US disclosed
US-7166586-B2 Sulfonamide lactam inhibitors of FXa and method BRISTOL MYERS SQUIBB CO. (US) 2007-01-23 — — US disclosed
US-7166586-B2 Sulfonamide lactam inhibitors of FXa and method BRISTOL MYERS SQUIBB CO. (US) 2007-01-23 — — US disclosed
US-20060003374-A1 Method of making PNA oligomers KIM SUNG K 2006-01-05 — — US disclosed
US-20050283005-A1 PNA monomer and precursor KIM SUNG K 2005-12-22 — — US disclosed
US-6969766-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-29 — — US disclosed
US-20050250785-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 — — US disclosed
US-20050250786-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 — — US disclosed
CN-1659153-A PNA monomer and precursor PANAGENE INC (KR) 2005-08-24 — — CN disclosed
EP-1501812-A1 PNA MONOMER AND PRECURSOR Panagene, Inc. (KR) 2005-02-02 — — EP disclosed
US-20030225252-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2003-12-04 — — US disclosed
WO-2003091231-A1 PNA MONOMER AND PRECURSOR PANAGENE, INC. (US) 2003-11-06 — — WO disclosed
US-4069259-A Process for preparing organic disulfides ALLIED CHEMICAL CORPORATION (US) 1978-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050283005-A1 PNA monomer and precursor PNISR, RNGTT, POLL SMN1; SMN2 1665/4885NPSR1 102/4885LOXL2 4392/4885
US-20050250785-A1 PNA monomer and precursor PNISR, RNGTT, POLL SMN1; SMN2 1665/4885NPSR1 102/4885LOXL2 4392/4885
US-20030225252-A1 PNA monomer and precursor PNISR, RNGTT, NCL SMN1; SMN2 1232/4885NPSR1 144/4885LOXL2 4403/4885
US-20050250786-A1 PNA monomer and precursor PNISR, RNGTT, NPR1 SMN1; SMN2 1887/4885NPSR1 69/4885LOXL2 4481/4885
US-20060003374-A1 Method of making PNA oligomers RNGTT, POLL, PNISR SMN1; SMN2 1917/4885NPSR1 76/4885LOXL2 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.